$CC

HOSTETTER SHANE purchased $50K of CC

HOSTETTER SHANE (Chief Financial Officer) purchased 3,350 shares of Chemours Co (CC) at $14.94 on 2026-08-06.

Original reporting
SEC EDGAR · HOSTETTER SHANE
Published Aug 10, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CC
Neutral
low confidence
Mentioned
$CC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CCNeutralLow
01

Why it matters

A CFO open-market purchase of $50,049 worth of CC shares is disclosed, but there is no accompanying operational or financial update in the text.

02

Market read

Traders may note the insider buy as a small sentiment input, but the filing alone is unlikely to drive a major repricing without other catalysts.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still provides no context on motivation, timing constraints, or whether other insiders are buying/selling.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10 after-hours (Form 4 timestamp 16:30 ET)

Background

The article is a SEC Form 4 insider transaction disclosure for Chemours (CC).

Company-level read

Ticker impact

$CCNeutralLow confidence
Context

Chemours CFO Shane Hostetter filed a Form 4 showing an open-market purchase of 3,350 shares at $14.94 on 2026-08-06.

Expected impact

Limited near-term impact; any effect is likely sentiment-driven and small.

Evidence & confidence

Form 4 insider purchases can be informative, but this transaction size and lack of accompanying company-specific news make it unlikely to move the stock materially on its own.

Market effects

No clear sector read-through from a single CFO open-market purchase.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification activity, and this Form 4 does not indicate a planned change in company outlook.

Key entities

  • Chemours Co

    Company whose insider transaction is disclosed via Form 4.

  • Shane Hostetter

    Chief Financial Officer reporting an open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CCMedAI 8/10

Environmental groups allege Chemours hasn't met PFAS limits agreement

Cape Fear River Watch alleges Chemours has failed to meet pollution limits agreed upon in a 2019 consent order, claiming the company's groundwater and air emissions controls are inadequate. Chemours disputes these claims, stating it has spent $1.2 billion complying with the order. The environmental group filed a formal notice, citing high levels of PFAS in surface water and groundwater around the plant.

$CCMed

Chemours (CC) Shares Jumped, What Is Behind The Latest Move?

Chemours (CC) shares rose 3.10% after agreeing to a settlement with North Carolina and nearby communities over emissions. The stock is at $14.98, down 29.24% over 90 days. Analysts view it as undervalued at a fair value of $19.78, citing growth in advanced materials and cost optimization. However, PFAS liabilities and regulations pose risks.

$CCMedAI 8/10

What Chemours (CC)'s PFAS Settlement Means For Shareholders

Chemours (CC), DuPont, and Corteva agreed to a US$455 million settlement over PFAS emissions, shared equally. Payments will span 15 years, adjusting cost accounting under a US$4 billion cap. Chemours aims to recover profits by 2029, with revenue and earnings projections of US$6.6 billion and US$686.0 million, respectively, despite current losses. Analysts highlight operational execution and PFAS liability management as key factors.

$CCMedAI 8/10

North Carolina, Chemical Companies Reach $455M PFAS Contamination Settlement

Chemours, DuPont, and Corteva agreed to pay $455M over 15 years to settle PFAS contamination claims in North Carolina. Chemours will cover half, with the rest split between DuPont and Corteva. The funds will support state and local remediation efforts. The companies have already spent or committed significant sums for cleanup and penalties.